Get the Stockscreener App
0.00
100.00%
-221.38
After Hours:
221.32
221.32
+
Cidara Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
See More
Previous Close:
$221.38
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$6.96B
Revenue:
$302.00K
Net Income/Loss:
$-117.10M
P/E Ratio:
0.00
EPS:
-11.13
Net Cash Flow:
$-129.13M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$221.42
52-Week Range:
$0.00
$221.42
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Name
Cidara Therapeutics Inc
Sector
Industry
Phone
858-752-6170
Address
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Compare CDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
0.00 | 6.96B | 302.00K | -117.10M | -129.13M | -11.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-17-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-17-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-17-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-16-25 | Initiated | Morgan Stanley | Overweight |
| Oct-10-25 | Initiated | JP Morgan | Overweight |
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Mar-12-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-27-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Nov-08-24 | Initiated | Guggenheim | Buy |
| Aug-14-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-03-21 | Resumed | H.C. Wainwright | Buy |
| Sep-22-21 | Upgrade | WBB Securities | Buy → Strong Buy |
| Mar-04-21 | Initiated | Aegis Capital | Buy |
| Sep-04-19 | Upgrade | Wedbush | Neutral → Outperform |
| Jul-26-18 | Initiated | Citigroup | Buy |
| Apr-21-17 | Initiated | Raymond James | Strong Buy |
| Apr-17-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-11-17 | Resumed | Wedbush | Outperform |
| Feb-22-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-17 | Upgrade | WBB Securities | Sell → Hold |
| Dec-21-16 | Resumed | Leerink Partners | Outperform |
| Dec-19-16 | Initiated | H.C. Wainwright | Buy |
| Sep-23-16 | Downgrade | WBB Securities | Hold → Sell |
| Oct-09-15 | Upgrade | WBB Securities | Sell → Hold |
| May-11-15 | Initiated | Jefferies | Buy |
| May-11-15 | Initiated | Leerink Partners | Outperform |
| May-11-15 | Initiated | Needham | Buy |
| May-11-15 | Initiated | Wedbush | Outperform |
| Apr-23-15 | Initiated | WBB Securities | Sell |
View All
Cidara Therapeutics Inc Stock (CDTX) Latest News
Promising Biotech Stocks To ConsiderJanuary 4th - MarketBeat
Cidara Therapeutics Completes Acquisition and Becomes Private Company - The Globe and Mail
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight - Benzinga
Will Cidara Therapeutics Inc. stock recover faster than marketEntry Point & AI Enhanced Trading Alerts - ulpravda.ru
Why Cidara Therapeutics Inc. stock appeals to analysts2025 Stock Rankings & Long Hold Capital Preservation Tips - ulpravda.ru
How sustainable is Cidara Therapeutics Inc. stock dividend payoutJuly 2025 Drop Watch & Free Real-Time Market Sentiment Alerts - ulpravda.ru
Will Cidara Therapeutics Inc. (20D0) stock outperform global peersWeekly Market Report & Consistent Profit Focused Trading Strategies - ulpravda.ru
RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck - Times Record News
Merck completes purchase of Calif. company for $9.2 billion, adds flu-prevention drug to portfolio - ROI-NJ
ulpravda ru > 2026> Is Cidara Therapeutics Inc. stock recession proofOil Prices & Stock Portfolio Risk Control - ulpravda.ru
Cidara Therapeutics, Inc. (CDTX) Investor Outlook: Analyzing the Biotech’s Strategic Position Amidst a Record 52-Week High - DirectorsTalk Interviews
What market sentiment indicators show for Cidara Therapeutics Inc. (20D0) stockEarnings Date Calendar & Outstanding Investment Portfolio - ulpravda.ru
Cidara therapeutics CEO Stein buys shares for $339k By Investing.com - Investing.com Canada
Merck (MRK) Finalizes Acquisition of Cidara Therapeutics - GuruFocus
Biotech Stocks To Follow NowJanuary 5th - MarketBeat
Merck to Complete Acquisition of Cidara Therapeutics - BioSpace
Cidara Therapeutics Announced Transfer or Voluntary Withdrawal of Listing - TradingView — Track All Markets
Merck completes purchase of biopharma company making experimental flu drug - WFMZ.com
Merck Sharp & Dohme LLC completed the acquisition of Cidara Therapeutics, Inc.. - MarketScreener
Merck (MRK) Completes Acquisition of Cidara Therapeutics (CDTX) for $9.2B - GuruFocus
Merck Successfully Completes Cash Tender Offer for Cidara Therapeutics - MarketScreener
Merck set to complete Cidara merger on Wednesday - breakingthenews.net
Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium - MSN
Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from S&P Biotechnology Select Industry Index - MarketScreener
Cidara Therapeutics (CDTX) rockets 722% in 2025 on Merck $9.2-billion merger - MSN
Biotech Stocks To Watch TodayJanuary 3rd - MarketBeat
Stock Watch: Biotech Acquisitions Drive Sector Momentum Going Into 2026 - Citeline News & Insights
Cidara Therapeutics stock hits 52-week high at 221.24 USD By Investing.com - Investing.com Nigeria
Top Biotech Stocks To Watch NowJanuary 2nd - MarketBeat
CDTX Stock Price, Forecast & Analysis | CIDARA THERAPEUTICS INC (NASDAQ:CDTX) - Chartmill
RSI Check: Will PROV stock outperform value stocksJuly 2025 Technicals & Proven Capital Preservation Methods - moha.gov.vn
Cidara Therapeutics (NASDAQ:CDTX) Hits New 12-Month HighHere's Why - MarketBeat
Cidara Therapeutics stock hits 52-week high at 221.24 USD - Investing.com
Merck stock in focus before Monday: Cidara deal deadline hits Jan. 6 as MRK sits near 52-week high - ts2.tech
How (CDTX) Movements Inform Risk Allocation Models - Stock Traders Daily
Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week - ts2.tech
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. - AOL.com
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? - sharewise.com
Cidara Therapeutics (CDTX) Rockets 722% in 2025 on Merck $9.2-Billion Merger - Insider Monkey
Meet the 10 Market Stars Behind Millionaire-Making in 2025 - Insider Monkey
Cidara Therapeutics Earnings Notes - Trefis
12 Overlooked Stocks That Delivered Massive Gains In 2025 - RTTNews
Best Biotech Stocks To Follow NowDecember 28th - MarketBeat
Biotech Stocks To ConsiderDecember 27th - MarketBeat
New Highs: Why Cidara Therapeutics Inc stock appeals to analystsWeekly Profit Recap & Daily Profit Focused Stock Screening - moha.gov.vn
Cidara Therapeutics (CDTX) CMO reports charitable gift of 450 shares - Stock Titan
Cidara: Merck's Acquisition Based On CD388 Flu Prevention Potential (NASDAQ:CDTX) - Seeking Alpha
Cidara Therapeutics Inc Stock (CDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):